Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Original Research

Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and detrimental adverse events for patients resulting from chemotherapy that can decrease the patient’s quality of life.
Oral oncolytic therapy is increasingly prescribed for patients with hematologic malignancies, but several barriers prevent or delay medication initiation, including insurance approval, financial assistance, limited distribution drug networks, and off-label use. Many oral therapies require insurance approval before they can be dispensed, and patients frequently need financial assistance for copays once a medication is approved.
Ovarian cancer has an annual incidence of 11.4 per 100,000 women in the United States, with a 5-year overall survival of 47.6% for all stages.1 In patients with fallopian tube or primary peritoneal ovarian cancer, a platinum-based (ie, carboplatin, cisplatin) regimen is the chemotherapy of choice in the metastatic or the adjuvant setting.2
Febrile neutropenia requires quick intervention with antipseudomonal beta-lactam antibiotics, such as piperacillin-tazobactam. Previous studies suggest that extended infusions may improve outcomes. The findings in this study show that use of extended infusions of piperacillin-tazobactam led to similar results as intermittent infusions, including defervescence, duration of antibiotic use, mortality, and antibiotic failure.
The sudden price increase of injectible calcitonin in 2015 prompted one institution to implement formulary restriction criteria to ensure optimal and cost-effective usee. The findings of this study show that using specific formulary restrictions and use criteria of calcitonin can appropriately reduce utilization and cost without affecting patient outcomes.
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.1 Current survival rates for pediatric ALL are approaching 90% in the United States.1,2 This has been accomplished by dose intensification, risk stratification, extended treatment duration, and central nervous system prophylaxis.1,2
Page 1 of 7
Results 1 - 10 of 67